Compare Stocks

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$5.49 -1.1%	$7.81	$5.28 ▼ $11.91	$451.50M	2.01	1.83 million shs	2.26 million shs
FATE Fate Therapeutics	$4.79 -5.0%	$6.95	$1.63 ▼ $8.83	$545.18M	1.66	2.78 million shs	2.69 million shs
HLVX HilleVax	$12.30 +3.7%	$16.09	$9.94 ▼ $20.22	$611.56M	0.65	137,798 shs	276,760 shs
JATT JATT Acquisition	$3.31 -10.3%	$3.63	$7.80 ▼ $12.38	$57.10M	N/A	41,322 shs	240,674 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	-1.07%	-15.65%	-28.39%	-31.40%	-31.40%
FATE Fate Therapeutics	-4.36%	-15.29%	-28.00%	+11.26%	-20.75%
HLVX HilleVax	-5.35%	-20.51%	-31.96%	-20.03%	-12.60%
JATT JATT Acquisition	+2.96%	+9.06%	+1.62%	-22.33%	-68.35%

Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDIT Editas Medicine	3.3533 of 5 stars	3.3	1.0	0.0	4.6	1.9	2.5	0.0
FATE Fate Therapeutics	4.2091 of 5 stars	4.0	1.0	0.0	4.7	2.6	2.5	0.6
HLVX HilleVax	3.6091 of 5 stars	3.5	5.0	0.0	0.0	3.2	5.0	0.0
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.56	Moderate Buy	$15.00	173.22% Upside
FATE Fate Therapeutics	2.08	Hold	$6.73	40.44% Upside
HLVX HilleVax	3.00	Buy	$30.67	149.32% Upside
JATT JATT Acquisition	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest EDIT, FATE, HLVX, and JATT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
3/28/2024	FATE Fate Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$2.00 ➝ $6.00
3/21/2024	HLVX HilleVax	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
3/19/2024	FATE Fate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
2/29/2024	EDIT Editas Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $16.00
2/29/2024	EDIT Editas Medicine	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $11.00
2/27/2024	EDIT Editas Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
2/27/2024	FATE Fate Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$3.00 ➝ $7.00
2/27/2024	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$6.00 ➝ $10.00
2/27/2024	FATE Fate Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Perform ➝ Market Perform	$6.00 ➝ $7.00
2/27/2024	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $7.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$78.12M	5.78	N/A	N/A	$4.27 per share	1.29
FATE Fate Therapeutics	$63.53M	8.58	N/A	N/A	$3.74 per share	1.28
HLVX HilleVax	N/A	N/A	N/A	N/A	$5.48 per share	N/A
JATT JATT Acquisition	N/A	N/A	$0.12 per share	27.08	($0.53) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$153.22M	-$2.05	N/A	N/A	N/A	-196.12%	-42.95%	-30.49%	5/3/2024 (Estimated)
FATE Fate Therapeutics	-$160.93M	-$1.64	N/A	N/A	N/A	-253.30%	-38.17%	-28.42%	5/1/2024 (Estimated)
HLVX HilleVax	-$123.57M	-$3.04	N/A	N/A	N/A	N/A	-48.17%	-38.05%	5/10/2024 (Estimated)
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A

Latest EDIT, FATE, HLVX, and JATT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/20/2024	Q4 2023	HLVX HilleVax	-$0.80	-$0.78	+$0.02	-$0.78	N/A	N/A
2/28/2024	Q4 2023	EDIT Editas Medicine	-$0.52	-$0.23	+$0.29	-$0.23	$4.84 million	$60.00 million
2/26/2024	12/31/2023	FATE Fate Therapeutics	-$0.57	-$0.45	+$0.12	-$0.45	$0.85 million	$1.68 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	5.39	5.39
FATE Fate Therapeutics	N/A	8.48	8.48
HLVX HilleVax	0.10	10.62	10.62
JATT JATT Acquisition	N/A	0.15	0.15

Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
FATE Fate Therapeutics	97.54%
HLVX HilleVax	86.42%
JATT JATT Acquisition	47.97%

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	2.20%
FATE Fate Therapeutics	5.04%
HLVX HilleVax	29.30%
JATT JATT Acquisition	20.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	265	82.24 million	80.01 million	Optionable
FATE Fate Therapeutics	181	113.82 million	94.24 million	Optionable
HLVX HilleVax	90	49.72 million	35.15 million	Not Optionable
JATT JATT Acquisition	2,021	17.25 million	13.80 million	Not Optionable

EDIT, FATE, HLVX, and JATT Headlines

Source	Headline
	Bahdarpur Jatt Pin Code indiatvnews.com - April 10 at 12:34 AM
	Nishikant Dubey, wife booked in med college acquisition case timesofindia.indiatimes.com - March 31 at 7:56 PM
	Sen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. Steel pennlive.com - December 22 at 12:48 PM
	Microsoft poised to close massive Activision Blizzard acquisition next week vg247.com - October 9 at 6:20 PM
	The Legend of Maula Jatt to be released in cinemas on Thursday radio.gov.pk - July 8 at 10:17 AM
	Pakistani film The Legend of Maula Jatt reunites South Asian communities in Antwerp Belgium radio.gov.pk - June 15 at 7:58 AM
	Zura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% Upside msn.com - May 24 at 5:21 PM
	I Am A Jaat. People Often Confuse Me For A Jatt. Here’s The Difference Between The Two scoopwhoop.com - April 28 at 7:22 PM
	Zura Bio Announces Appointment of Chief Scientific Officer businesswire.com - April 16 at 10:12 AM
	TalkTalk, the Issa brothers and AO: The 19 latest deals from across the North West msn.com - March 30 at 10:10 AM
	Zura Bio Limited Announces Share Redemptions and Lock-up Agreement finance.yahoo.com - March 27 at 1:00 PM
	Tesla, Coinbase, Chewy, JATT Acquisition, Manchester United: Why These 5 Stocks Are Drawing Investors' Attention Today benzinga.com - March 23 at 12:27 AM
	Cheshire biotech start-up raises $65m in New York float in further snub to London Stock Exchange msn.com - March 21 at 7:04 PM
	Newly public Zura Bio stock falls 11% following Nasdaq debut seekingalpha.com - March 21 at 7:04 PM
	Another British tech firm opts for a New York listing as UK’s science superpower dreams fade cityam.com - March 21 at 9:03 AM
	Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp finance.yahoo.com - March 21 at 9:03 AM
	A gandasa from 'The Legend of Maula Jatt' auctioned for $50,000 tribune.com.pk - March 17 at 7:19 PM
	JATT Acquisition shareholders approve business combination with Zura Bio msn.com - March 16 at 7:03 PM
	JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited finance.yahoo.com - March 16 at 7:03 PM
	JATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited businesswire.com - March 13 at 9:33 AM
	SPAC JATT to hold shareholders vote on Zura Bio merger on March 16 msn.com - March 2 at 3:17 PM
	JATT Acquisition Corp’s Proposed Business Combination With Zura Bio Limited Declared Effective by US SEC finance.yahoo.com - March 2 at 3:17 PM
	JATT Acquisition Corp (NYSE:JATT) is a favorite amongst institutional investors who own 54% finance.yahoo.com - February 25 at 11:59 AM
	Elon Musk reportedly planning to cut 50% jobs at Twitter: report timesnownews.com - October 31 at 5:38 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Robinhood’s Credit Card Has Call Option Buyers Coming in Hot
April 3, 2024 8:45 AM
View Robinhood’s Credit Card Has Call Option Buyers Coming in Hot
Here are the Pros and Cons of Using Options Put Credit Spreads
April 18, 2024 8:20 AM
View Here are the Pros and Cons of Using Options Put Credit Spreads

All Headlines

Company Descriptions

Editas Medicine

NASDAQ:EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Fate Therapeutics

NASDAQ:FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

HilleVax

NASDAQ:HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

JATT Acquisition

NYSE:JATT

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial